A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP ...
Experts say that improving heart and metabolic health may be key to helping people with severe mental illness live longer, ...
A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p ...
These findings are particularly relevant given the growing number of patients admitted to the ICU who are receiving GLP-1 ...
Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.
This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, ...
A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p 54% of participants on the 24 mg dose achieved resolution of obesity (BMI C ...
More than one-quarter of adults aged 25 to 64 years from 99 countries are eligible to receive a GLP-1 receptor agonist.
Young, affluent and health‑driven, GLP‑1 users are reshaping food retail with demand for protein‑rich, nutrient‑dense and convenient meals.
27.0 percent of the total pooled sample eligible, with higher eligibility seen in higher-income countries and for women.
University Hospitals cardiologist explains the benefits, side effects, and future of these increasingly popular drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results